Company intelligence / Profile preview

AIMMED

Ownership: Private
Development stage: Commercial

Overview

AIMMED develops evidence-based digital therapeutics for mental health and psychiatric indications. Its products leverage cognitive and neurobehavioral mechanisms, with demonstrated safety and clinical effectiveness. The company has an expanding pipeline across multiple disease areas since 2019, aiming to deliver more effective, personalized software-based treatments for patients globally

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapyDigital therapeutic (software-based intervention)
Industry: Digital Health Medical Devices

Drug pipeline

2 assets

Somzz

Commercial

Indications: Insomnia

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AIMMED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIMMED.

Explore the full profile